Successful Empirical Treatment of Severe Pneumocystis carinii Pneumonia in Immunocompromised Children

Felix Liauw^1, , Windhi Kresnawati¹ and Nastiti Kaswandani²

¹Department of Child Health, Faculty of Medicine, University of Indonesia

²Division of Respirology, Department of Child Health, Faculty of Medicine, University of Indonesia

Cite this paper

Felix Liauw, Windhi Kresnawati and Nastiti Kaswandani. Successful Empirical Treatment of Severe Pneumocystis carinii Pneumonia in Immunocompromised Children. American Journal of Medical Case Reports. 2016; 4(6):208-211. doi: 10.12691/AJMCR-4-6-6

Abstract

Immunocompromised patients are very prone to infection and sometimes result in death. Pneumocystis carinii pneumonia (PCP) is one of the opportunistic infections that affects lung. The frequency was high (80-88%). We reported 2 severe cases of PCP infection that remain survive. Case 1 is 8-year-old boy, post-liver transplantation, with PCP, pulmonary tuberculosis, cytomegalovirus infection, septic shock and severe malnutrition. Case 2 is 8-year-old girl, HIV positive, with PCP, respiratory failure, and severe malnutrition. These patients survived after adequate treatment of PCP and nutritional support. After 26 months of follow up, they are doing well with good nutritional status.

Keywords

pneumocystis carinii, pneumonia, immunocompromised, children

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Wilkin A, Feinberg J. Pneumocystis carinii pneumonia: a clinical review. Am Fam Physician. 1999;60(6):1600-1708.
[2]	Thomas CF Jr, Limper AH.. Current insights into the biology and pathogenesis of pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298-308.
[3]	Cushion MT. Pneumocystis: untraveling the cloak of obscurity. Trends Microbiol. 2004;12(7):243-9.
[4]	Morrow BM, Samuel CM, Zampolil M, Whitelaw A, Zar HJ. Pneumocystis pneumonia in South African children diagnosed by molecular methods. BMC Res Notes. 2014;7(1):26-34.
[5]	Connor E, Bagarazzi M, McSherry G, Holland B, Boland M, Denny T, et al. Clinical and laboratory correlates of pneumocystis carinii pneumonia in children infected with HIV. JAMA. 1991;265(13):1693-7.
[6]	Zar HJ, Dechaboon A, Hanslo D, Apolles P,Magnus KG, Hussey G. Pneumocystis carinii pneumonia in south African children infected with human immunodeficiency virus. Pediatr Infect Dis J. 2000;19(7):603-7.
[7]	Graham SM, Mitmila EI, Kamanga HS, Walsh AL, Hart CA, Molyneux ME. Clinical presentation and outcome of pneumocystis carinii pneumonia in Malawain children. Lancet. 2000;355(9201):369-73.
[8]	Jeena PM, Coovadia HM, Chrystal V. Pneumocystis and cytomegalovirus infection in severely ill, HIV-infected African infants. Ann Trop Paediatr. 1996;16(4):361-8.
[9]	Cherian T, Ramakrishna B, Babu PG, John TJ, Raghupathy P. Pneumocystis carinii pneumonia in pediatric acquired immunodeficiency syndrome. Indian J Pediatr. 1997;34(6):550-4.
[10]	Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131(4):1173-80.
[11]	Borstnar S, Lindic J, Tomazic J, Kandus A, Pikelj A, Prah J, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national cancer experience. Transplant Proc. 2013;45(4):1614-7.
[12]	Samuel CM, Whitelaw A, Corcoran C, Morrow B, Hsiao NY, Zampoli M, et al. Improved detection of pneumocystis jirovecii in upper and lower respiratory tract specimens from children with suspected pneumocystis pneumonia using real-time PCR: a prospective study. BMC Infect Dis. 2011;11:329-35.
[13]	Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med. 1998;338(13):853-60.
[14]	Ledergerber B, Egger B, Erard V. AIDS related opportunistic illness occurring after initiation of potent antiretroviral therapy: the swiss HIV cohort study. JAMA. 1999;282(23):2220-6.
[15]	Costa MC, Helweg-Larsen J, Antunes F, Lungren B, Diogo J, Matos O. PCR-RFLP analysis of the DHPS gene for the study of resistance o penumocystis carinii to sulpha drugs in patients with co-infection PCP/HIV. J Eukaryot Microbiol. 2001;suppl:148-9.
[16]	Rabodonirina M, Vaillant L, Taffe P, Nahimana A, Gillibert RP, Vanhems P, et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerg Infect Dis. 2013;19(1):21-8.
[17]	Joffrion M, Cushion MT. Sterol biosynthesis and sterol uptake in the fungal pathogen pneumocystis carinii. FEMS Microbiol Lett. 2010;311(1):1-9.
[18]	Mohar A, Romo J, Salido F. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in mexico. AIDS. 1992;6(5):467-73.
[19]	Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in HIV type 1-infected children. Clin Infect Dis. 2000;31(1):170-6.
[20]	Wong HR, Chundu KR. Improved outcome for young children with AIDS, Pneumocystis carinii pneumonia, and acute respiratory failure. Pediatr Pulmonol. 1994;18(2):114-8.
[21]	Walzer PD, Evans HER, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46(4):625-33.
[22]	Radhi S, Alexander T, Ukwu M, Saleh S, Morris A. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis. 2008;8:118-27.
[23]	Fei MW, Kim EJ, Sant CA, Jarlsberg LG, Davis JL, Swartzman A, et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax. 1999;64(12):1070-6.